FINWIRES · TerminalLIVE
FINWIRES

国际能源署署长警告:中东冲突或致1300万桶/日石油供应中断

-- 国际能源署执行主任法提赫·比罗尔周一表示,由于中东冲突,全球石油供应中断已达每日约1300万桶,他称这是有史以来对能源安全的最大威胁。 比罗尔是在大西洋理事会组织的一次活动上发表上述讲话的。 比罗尔表示,目前的油气供应中断规模已超过以往任何危机,包括俄罗斯入侵乌克兰后损失的750亿立方米天然气。 比罗尔警告说,能源基础设施的破坏正在加剧危机,并补充说,即使局势迅速好转,恢复中断的供应系统也需要相当长的时间。 比罗尔表示,包括油田、天然气站和炼油厂在内的80多个能源设施遭到破坏,并补充说,“超过三分之一的设施……损毁非常严重”,这凸显了供应中断的规模。 他补充说,各国的复苏情况将有所不同,金融能力较弱的国家可能需要更长时间才能复苏,并表示恢复到危机前水平可能需要“长达两年”,这凸显了长期供应风险。 比罗尔表示,他希望无需再次紧急释放石油储备,并补充说:“我非常希望我们不需要这样做,但如果需要,我们已做好立即行动的准备。” 国际能源署此前于3月11日宣布,其32个成员国一致同意从紧急储备中释放4亿桶石油,以缓解与中东冲突相关的石油市场动荡。 他补充说,国际能源署正在密切关注局势,并随时准备在必要时部署更多储备,以帮助稳定全球石油市场。 国际能源署署长表示,油价“……已经很高,但并未反映出问题的严重性”,并警告称,随着局势更加明朗,市场可能会出现剧烈调整。 比罗尔表示,价格仍然与基本面脱节,他称目前的情况为“脱节”。 “……我认为我们很快就会看到价格趋于一致,这当然对全球经济来说是一个极其敏感的问题,”他说道。 比罗尔指出,这场危机不仅限于能源,“化肥、石化产品、氦气等重要商品”也正面临每日短缺,这凸显了全球供应链面临的风险。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703